19 Dec 2022 FINTEPLA®▼ (fenfluramine) oral solution recommended for approval in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) Member news
08 Nov 2022 New Idylla™ EGFR study shows reduction of time-to-treatment by 48% for lung cancer patients Member news
10 Oct 2022 Biocartis initiates commercialization in Europe of HepatoPredict (CE-IVD) test for liver cancer patients Member news
07 Sep 2022 New three-year BIMZELX®▼ (bimekizumab) data reinforce long-term maintenance of complete skin clearance in moderate to severe plaque psoriasis Member news
01 Sep 2022 Biocartis initiates commercialization in Europe of SkylineDx’s innovative Merlin™ Assay (CE-IVD) for melanoma patients Member news
11 Aug 2022 argenx announces European Commission approval of VYVGART™ (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis Member news
05 Jul 2022 ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder Member news
21 Jun 2022 New agreement paves way for development of first African-owned COVID-19 vaccine Member news
31 May 2022 argenx announces the UK MHRA has granted early access to efgartigimod for generalized myasthenia gravis Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
